Nonsurgical Treatments for Erectile Dysfunction: Oral, Topical, Intracavernous, and Vacuum Devices
The availability of vasoactive drugs for intracavernosal injection has been one of the most significant milestones in the treatment of male erectile dysfunction. It has allowed meticulous investigation of the physiologic process of penile erection and opened up viable therapeutic alternatives for the patient with mild to moderate alterations at the level of the corpora. Equally important, the advent of injectable vasoactive drugs has permitted large strides in our understanding of the physiologic mechanisms of erection. The elucidation of many of those mechanisms at the cellular level has permitted the development of therapeutic strategies based on sound pharmacologic principles. We are getting closer to the availability of effective, noninvasive medications. This accomplishment is not the result of fortuitous progress: it is the culmination of dedicated and applied research to an area that for decades has remained in the background of medical interest.
KeywordsPlacebo Morphine Prolactin PGE1 Infertility
Unable to display preview. Download preview PDF.
- 1.Heaton J: Penile erections: what, where, when and how? In Pharmacotherapy of Erectile Dysfunction. Seminar 9771. American Urological Association; 1997.Google Scholar
- 7.Montague DK, Barada JH, Belker AM, et al.: Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996, 157:2006–211.Google Scholar
- 11.McMahon CG: A pilot study of the role of intracavernous injection of vasoactive intestinal peptide and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impotence Res 1996, 8:233–236.Google Scholar
- 12.Porst H: Vasoactive substances in erectile dysfunction: a survey of 10 years global experience. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1977:175–196.Google Scholar
- 18.Boolell M, Allen MJ, Ballard SA, et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 1996, 8:47–52.Google Scholar
- 23.Morales A, Bain J, Ruijs A, et al.: Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impotence Res 1996, 8:95–97.Google Scholar
- 26.Lewis R: Twenty years of vacuum therapy for erectile dysfunction in the United States. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1997:162–174.Google Scholar
- 33.Giuliano F, Jardin A, Gingell CJ, et al.: Sildenafil, an oral treatment for erectile dysfunction: a 1-year, open-label extension study [abstract]. Br J Urol 1997, 80:93.Google Scholar
- 35.Padma-Nathan H, Sildenafil Study Group: Oral Viagra in the treatment of erectile dysfunction: assessment of erections hard enough for sexual intercourse. J Urol 1998, (suppl): in press.Google Scholar